Study on the value of serum CXCL4L1, PSA combined with ultrasonic parameters in predicting Gleason grade after prostate cancer surgery
-
摘要 目的:探讨血清CXC趋化因子配体4L1(CXCL4L1)、前列腺特异抗原(PSA)联合超声参数对前列腺癌术后格里森(Gleason)分级的预测价值。方法:选取2021年6月至2022年12月江西省新余市人民医院行经尿道前列腺电切术治疗的100例前列腺癌患者为研究对象,根据术后Gleason分级分为低中危组(Gleason评分≤7分,70例)、高危组(Gleason评分≥8分,30例);比较两组血清CXCL4L1、总前列腺特异抗原(tPSA)、游离前列腺特异抗原(fPSA)水平及超声参数[前列腺特异抗原密度(PSAD)、前列腺内腺特异抗原密度(IGPSAD)、前列腺外腺特异抗原密度(EGPSAD)、超声评分];评价血清CXCL4L1、f PSA、tPSA、超声参数对术后Gleason分级的预测价值。结果:高危组血清CXCL4L1、f PSA、tPSA水平高于低中危组,PSAD、IGPSAD、EGPSAD、超声评分高于低中危组(P＜0.05);血清CXCL4L1、fPSA、tPSA、超声参数联合预测术后Gleason分级的AUC大于各指标单独预测(P＜0.05)。结论:血清CXCL4L1、PSA、超声参数与前列腺癌术后Gleason分级、临床病理特征密切相关,联合检测其水平对术后Gleason分级具有一定预测价值。
-
关键词
- 前列腺癌 /
- Gleason分级 /
- CXC趋化因子配体4L1 /
- 前列腺特异抗原 /
- 直肠超声
Abstract Objective: To investigate the predictive value of serum CXC chemokine ligand 4L1(CXCL4L1) and prostate specific antigen(PSA) combined with ultrasonic parameters for Gleason grade after prostate cancer surgery. Methods: A total of 100 patients with prostate cancer who underwent transurethral resection of prostate in Xinyu People's Hospital of Jiangxi Province from June 2021 to December 2022 were selected as the research subjects and divided into low-medium risk group(Gleason score≤7, 70 cases) and high-risk group(Gleason score≥8, 30 cases) according to postoperative Gleason grade. The levels of serum CXCL4L1, total prostate specific antigen(tPSA), free prostate specific antigen(fPSA), and ultrasound parameters [prostate specific antigen density(PSAD), prostate internal gland specific antigen density(IGPSAD), prostate external gland specific antigen density(EGPSAD), ultrasound score] were compared between the two groups. The predictive value of serum CXCL4L1, fPSA, tPSA, and ultrasound parameters for postoperative Gleason grade was evaluated. Results: The serum levels of CXCL4L1, fPSA, and tPSA in the high-risk group were higher than those in the low-medium risk group, while PSAD, IGPSAD, EGPSAD, and ultrasound scores were higher than those in the low-medium risk group(P＜0.05); the AUC predicted by the combination of serum CXCL4L1, fPSA, t PSA, and ultrasound parameters for postoperative Gleason grade was greater than that predicted by each indicator alone(P＜0.05). Conclusion: Serum CXCL4L1, PSA and ultrasound parameters are closely related to the Gleason grade and clinicopatho-logical features after prostate cancer surgery. The combined detection of CXCl4L1 and PSA levels has certain value in predicting the Gleason grade after prostate cancer surgery. -
-
[1] WILLIAMS I S, MCVEY A, PERERA S, et al. Modern paradigms for prostate cancer detection and management[J].The medical journal of Australia,2022,217(8):424-433.
[2] WANG X C, ZHANG Y, JI Z G, et al. Old men with prostate cancer have higher risk of Gleason score upgrading and pathological upstaging after initial diagnosis:a systematic review and meta-analysis[J]. World journal of surgical oncology, 2021, 19(1):18.
[3] LU X, ZHANG S L, LIU Z Y, et al. Ultrasonographic pathological grading of prostate cancer using automatic region-based Gleason grading network[J]. Computerized medical imaging and graphics, 2022, 102:102125.
[4] OMRI N, KAMIL M, ALEXANDER K, et al. Association between PSA density and pathologically significant prostate cancer:the impact of prostate volume[J]. The prostate, 2020, 80(16):1444-1449.
[5] ZHANG M, GUAN J, HUO Y L, et al. Downregulation of serum CXCL4L1 predicts progression and poor prognosis in prostate cancer patients treated by radical prostatectomy[J]. Asian journal of andrology, 2019, 21(4):387-392.
[6] CHIU P K F, AHMED H U, RASTINEHAD A R. TRUS biopsy vs transperineal biopsy for suspicion of prostate cancer[J]. Urology, 2022, 164:18-20.
[7] 赫捷,陈万青,李霓,等.中国前列腺癌筛查与早诊早治指南(2022,北京)[J].中华肿瘤杂志, 2022, 44(1):29-53. HE J, CHEN W Q, LI N, et al. China guideline for the screening and early detection of prostate cancer(2022, Beijing)[J]. Chinese journal of oncology, 2022, 44(1):29-53.
[8] SUN C W, YANG D R, ZHU J, et al. Modified the 8th AJCC staging system for patients with advanced prostate cancer:a study based on SEER database[J]. BMC urology, 2022, 22(1):185.
[9] 张胜捷,姜伟,袁逸民,等.改良Gleason评分系统在前列腺癌术后患者预后评估中的意义[J].中华泌尿外科杂志, 2016, 37(5):344-348. ZHANG S J, JIANG W, YUAN Y M, et al. Prognostic significance of modified Gleason scoring system after radical prostatectomy[J]. Chinese journal of urology, 2016, 37(5):344-348.
[10] EPSTEIN J I, EGEVAD L, AMIN M B, et al. The 2014 international society of urological pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma:definition of grading patterns and proposal for a new grading system[J]. The American journal of surgical pathology, 2016, 40(2):244-252.
[11] 孙军,董凤林,沈伟东,等.前列腺癌超声表现与Gleason评分的关系[J].中国医学影像学杂志, 2017, 25(12):941-943. SUN J, DONG F L, SHEN W D, et al. Relationship between ultrasonic manifestations in prostate cancer and gleason score[J]. Chinese journal of medical imaging,2017, 25(12):941-943.
[12] BIKFALVI A, BILLOTTET C. The CC and CXC chemokines:major regulators of tumor progression and the tumor microenvironment[J]. American journal of physiology Cell physiology, 2020, 318(3):C542-C554.
[13] REYNDERS N,ABBOUD D, BARAGLI A, et al. The distinct roles of CXCR3 variants and their ligands in the tumor microenvironment[J]. Cells, 2019, 8(6):613.
[14] LONERGAN P E, JEONG C W, WASHINGTON S L 3rd,et al. Active surveillance in intermediate-risk prostate cancer with PSA 10-20 ng/mL:pathological outcome analysis of a population-level database[J]. Prostate cancer and prostatic diseases, 2022, 25(4):690-693.
[15] VENKATESAN A M,MUDAIRU-DAWODU E, DURAN C H, et al. Detecting recurrent prostate Cancer using multiparametric MRI, influence of PSA and Gleason grade[J].Cancer imaging, 2021, 21(1):3.
[16] VILSON F L, LI S F, BROOKS J D, et al. Sudden PSA rise to≥20 ng/ml and prostate cancer diagnosis in the United States:a population-based study[J]. The prostate,2020, 80(16):1438-1443.
[17] HÄGGMAN M, DAHLMAN P, AHLBERG M, et al. Biparametric MRI/TRUS fusion targeted repeat biopsy after systematic 10-12 core TRUS-guided biopsy reveals more significant prostate cancer especially in anteriorly located tumors[J]. Acta radiologica open, 2022, 11(3):20584601221085520.
[18] WANG C M, YUAN L, SHEN D Y, et al. Combination of PI-RADS score and PSAD can improve the diagnostic accuracy of prostate cancer and reduce unnecessary prostate biopsies[J]. Frontiers in oncology, 2022, 12:1024204.
[19] WEI X T, XU J M, ZHONG S Y, et al. Diagnostic value of combining PI-RADS v2.1 with PSAD in clinically significant prostate cancer[J]. Abdominal radiology, 2022,47(10):3574-3582.
[20] ALANEE S, DEEBAJAH M, DABAJA A, et al. Utilizing lesion diameter and prostate specific antigen density to decide on magnetic resonance imaging guided confirmatory biopsy of prostate imaging reporting and data system score three lesions in African American prostate cancer patients managed with active surveillance[J]. International urology and nephrology, 2022, 54(4):799-803.
[21] CHOE S, PATEL H D, LANZOTTI N, et al. MRI vs transrectal ultrasound to estimate prostate volume and PSAD:impact on prostate cancer detection[J]. Urology, 2023,171:172-178.
-
期刊类型引用(4)
1. 韩淑杰，庞洪波，董艳霞. PSA、PCA3联合超声图像对前列腺癌穿刺活检的诊断价值. 分子诊断与治疗杂志. 2025(02): 370-373 . 
百度学术
2. 刘晓丽，黄朝康，庞文帅，朱磊. Periostin在前列腺癌中表达及与Gleason分级的相关性. 中国老年学杂志. 2024(10): 2355-2358 . 百度学术
3. 马小静，郝巧梅，张海三. 动态对比增强磁共振成像指标与表观扩散系数值在前列腺癌诊断中的应用价值. 实用医学影像杂志. 2024(06): 426-429 . 百度学术
4. 邵长帅，任小强，王鸿渊. 与前列腺癌根治术患者临床特征及预后的关系. 癌症进展. 2024(23): 2616-2619 . 百度学术
其他类型引用(0)
计量
- 文章访问数: 48
- HTML全文浏览量: 2
- PDF下载量: 12
- 被引次数: 4
下载:
